Smoking cessation: Difference between revisions
Jump to navigation
Jump to search
imported>Joe Quick m (subpages) |
imported>Pierre-Alain Gouanvic No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
==Etiology== | |||
'''Tobacco smoking as self-medication''' | |||
==Medications== | ==Medications== | ||
===Rimonabant=== | ===Rimonabant=== | ||
Revision as of 22:49, 13 January 2008
Etiology
Tobacco smoking as self-medication
Medications
Rimonabant
Rimonabant, a selective type 1 cannabinoid (CB1) receptor antagonist, improve smoking cessation and moderate weight gain associated with smoking cessation according to a meta-analysis of randomized controlled trials by the Cochrane Collaboration.[1] However, "there is current concern (August 2007) over rates of depression and suicidal thoughts in people taking rimonabant for weight control."[1]
References
- ↑ 1.0 1.1 Cahill K, Ussher M (2007). "Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation". Cochrane Database Syst Rev (4): CD005353. DOI:10.1002/14651858.CD005353.pub3. PMID 17943852. Research Blogging.